Videos

Gabriel Hinojosa, PharmD, BCOP, looks beyond frontline regimens in multiple myeloma, and discusses treatment options, adverse events, and complexities in sequencing therapies.

Robert Mancini, PharmD, reviews pharmacists’ pivotal role in operationalizing use of bispecifics in diffuse large B-cell lymphoma (DLBCL), overcoming challenges, and supporting direct patient care teams.

A panel of experts share insights on overcoming challenges in responsible opioid prescribing and explore emotional responses, aversion to change, and the role of interdisciplinary collaboration in addressing the opioid crisis.

Kristen Peterson, PharmD, BCOP, explores how pharmacists deliver comprehensive education, empower patients, manage adverse effects, and prioritize outcomes for multiple myeloma care, ensuring quality treatment understanding and adherence.

Experts discuss patient advocacy, empowering patients in accessing treatments, educating them about health care systems, and collaborating with health care providers for better myelofibrosis management.

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, and Amir Ali, PharmD, BCOP, FHOPA, delve into bispecific antibody treatments, focusing on strategies for patient safety and optimizing care in the management of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome.

Robert Mancini, PharmD, discusses bispecific therapy advancements and strategies to manage adverse effects in diffuse large B-cell lymphoma (DLBCL) care, offering insights on toxicity phases, monitoring, and patient care.

Jennifer Marsh, PharmD, BCCCP, discusses the current standard of care for hepatic encephalopathy, highlighting challenges in treatment, prescription drug coverage, transition of care, and outpatient treatment access.

Expert colleagues explore responsible opioid management strategies and discuss addressing biases affecting prescribing practices across demographics and replacing stigmatizing language to improve patient outcomes; they also review practical approaches to creating ethical, equitable, and patient-centered opioid stewardship programs.

Gabriel Hinojosa, PharmD, BCOP, provides insights on selecting the best treatment regimen, and considers comorbidities, adverse events, and therapy modifications in multiple myeloma treatment.

Shawn Griffin, PharmD, BCOP, reviews strategies to tackle socioeconomic challenges in myelofibrosis treatment, covering costs, transportation, language barriers, cultural sensitivity, and patient communication.

Pharmacists discuss tailored patient education approaches, emphasizing key medication details, side effects, and financial aspects critical for myelofibrosis care, optimizing adherence and healthcare outcomes.

Panelists explore the challenges, implementations, and decision-making processes surrounding bispecific treatments in diffuse large B-cell lymphoma (DLBCL).